EpiCast Report on Global Insomnia Market Epidemiology Forecast to 2023

<strong>EpiCast</strong> <strong>Report</strong>:
Insomnia -
Epidemiology Forecast
to 2023
www.bigmarketresearch.com

<strong>Report</strong> Description
Acquired (Autoimmune) Hemolytic Anemia
GlobalData epidemiologists forecast that the total prevalent cases of acute insomnia in
the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156
total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. GlobalData
epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not
fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to
67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated
23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of
total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%.
GlobalData epidemiologists forecast that the total prevalent cases of chronic secondary
insomnia in the 7MM will increase from 53,697,425 total prevalent cases in 2013, to
57,525,122 total prevalent cases in 2023 at an AGR of 0.71%.
Read complete report here @
http://www.bigmarketresearch.com/epicast-report-insomnia-epidemiology-forecastto-2023-market

<strong>Report</strong> Description
Acquired (Autoimmune) Hemolytic Anemia
Insomnia is a highly prevalent condition; approximately one third of the general
population presents with some degree of insomnia.
GlobalData epidemiologists used comprehensive country-specific data from populationbased
studies published in peer-reviewed journal articles to arrive at a meaningful, indepth
analysis and forecast for the total prevalent cases of acute insomnia, chronic
insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary
insomnia in the 7MM, based on the DSM-IV criteria. For all the 7MM, the total prevalent
cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary
insomnia, and chronic secondary insomnia were segmented by age and sex, which
facilitates an understanding of the distribution of the disease within the population and
informs strategies to improve the management of the disease. Furthermore, the forecast
methodology is consistent across each of the 7MM, thereby allowing for a meaningful
comparison of the forecast total prevalent cases among each market.
Get enquire about report here @
http://www.bigmarketresearch.com/report-enquiry/178077

Table Of Contents
Acquired (Autoimmune) Hemolytic Anemia
1. Introduction
• Catalyst
• Related <strong>Report</strong>s
• Upcoming Related <strong>Report</strong>s
2. Europe Refining Industry
• Disease Background
• Risk Factors and Comorbidities
• Global Trends
• Forecast Methodology
• Sources Used
• Sources Not Used
• Forecast Assumptions and Methods
• Epidemiological Forecast for Acute Insomnia (2013-2023)

Table Of Contents
Acquired (Autoimmune) Hemolytic Anemia
3. Appendix
• Bibliography
• About the Authors
• Epidemiologists
• Reviewers
• Global Director of Therapy Analysis and Epidemiology
Get complete TOC @ http://www.bigmarketresearch.com/epicast-report-insomniaepidemiology-forecast-to-2023-market

<strong>Report</strong> Description
Acquired (Autoimmune) Hemolytic Anemia
Reasons to buy
• Develop business strategies by understanding the trends shaping and driving the
global insomnia market.
• Quantify patient populations in the global insomnia market to improve product
design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that
present the best opportunities for insomnia therapeutics in each of the markets
covered.

FOR MORE DETAILS
Visit us at :
http://www.bigmarketresearch.com/epicast-report-insomniaepidemiology-forecast-to-2023-market
Stay With Us:
TELEPHONE: +1 (855) 711-1555
E-MAIL: help@bigmarketresearch.com
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States